We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

5 hedge funds and large institutions have $9K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less funds holding

Funds holding: 6 → 5 (-1)

36% less capital invested

Capital invested by funds: $14K → $9K (-$5K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CCB
Cutter & Co Brokerage
Missouri
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$5K – – –
BO
2
BRR OpCo
Ohio
$2K – – –
ACM
3
Academy Capital Management
Texas
$1K – – –
QCIG
4
Quad-Cities Investment Group
Iowa
$1K – – –
CCB
5
Cutter & Co Brokerage
Missouri
– -$2K -28,500 Closed

PVCT Hedge Fund Activity: Q4 2018 in Review

5 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2018, worth a combined $9K — down 36% from $14K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PVCT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Cutter & Co Brokerage, exiting entirely with an estimated $2K sold.

  • 5 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2018, down from 6 in Q3 2018.
  • Funds reported $9K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2018, down 36% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2018 and 1 closed out, a net change of -1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2018 was Cutter & Co Brokerage, an estimated $2K sold.

Based on aggregated 13F filings for Q4 2018.